Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Original Article

Evaluation of Synergism between Cefotaxime and Allium sativum against Extended-spectrum beta-lactamase and Ambler class C co-producers

Pratibha J. Shah, Manita T. Williamson.

The present study evaluates the synergistic association between Cefotaxime and aqueous garlic (Allium sativum) extract (AGE) on Extended spectrum beta-lactamase (ESBL) and Ambler Class C (AmpC) co-producing E.coli strains from Skin and soft tissue infections (SSTIs). Ceftazidime-resistant E.coli strains were screened for beta-lactamase production by Phenotypic confirmatory disc diffusion test (PCDDT) and E-test. Antibacterial activity of AGE was examined by the disc diffusion method and the minimum inhibitory concentration (MIC) of Cefotaxime and AGE was determined. The synergistic association between Cefotaxime and AGE was evaluated by calculating the fractional inhibitory concentration (FIC) index, time-kill kinetics assay (TKA) and scanning electron microscopy (SEM). The zone of inhibition by AGE against the 27 E.coli co-producers of ESBL and AmpC ranged from 17- 30 mm. The average MIC of Cefotaxime and AGE was found to be 570 μg/ml and 0.86% (4.28 mg/ml), respectively. The FIC index obtained by Checkerboard method established a synergistic association between Cefotaxime and AGE in 10 (37%) test strains, which was confirmed by TKA. The SEM analysis revealed complete cell degradation at 8 h on treatment with Cefotaxime-AGE combination. It can be stated that AGE may aid Cefotaxime in treatment of beta-lactamase producing E.coli strains from SSTIs.

Key words: Beta-lactamase, Cefotaxime, Aqueous garlic extract, Synergy, Time-kill kinetics assay, SEM

Share this Article

Journal of Interdisciplinary Histopathology


BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.